References
- Sulek K. Prize in 1908 awarded to P Ehrlich and E Metchnikoff for their work in immunology. Wiad. Lek.20, 1117–1118 (1967).
- Ehrlich P. The partial function of cells: Nobel prize address given on 11 December 1908 at Stockholm. Int. Arch. Allergy Appl. Immunol.5, 67–86 (1954).
- Siegel JH, Janis R, Alper JC, Schutte H, Robbins L, Blaufox MD. Disseminated visceral Kaposi’s sarcoma. Appearance after human renal homograft operation. JAMA207, 1493–1496 (1969).
- Myers BD, Kessler E, Levi J, Pick A, Rosenfeld JB, Tikvah P. Kaposi sarcoma in kidney transplant recipients. Arch. Intern. Med.133, 307–311 (1974).
- Penn I. Kaposi’s sarcoma in organ transplant recipients: report of 20 cases. Transplantation27, 8–11 (1979).
- Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N. Engl. J. Med.348, 1681–1691 (2003).
- Stebbing J, Bower M. What can oncologists learn from HIV? Lancet Oncol.4, 438–445 (2003).
- Klein G, Sjorgen HO, Klein E, Hellstrom KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res.20, 1561–1562 (1960).
- Klein G. Tumor antigens. Annu. Rev. Microbiol.20, 223–252 (1966).
- Burnet FM. Immunological aspects of malignant disease. Lancet1, 1171–1174 (1967).
- Burnet FM. Immunological surveillance in neoplasia. Transplant Rev.7, 3–25 (1971).
- Bayer R, Oppenheimer GM. AIDS Doctors, Voices from the Epidemic: an Oral History. Oxford University Press, Oxford, UK (2002).
- Stebbing J, Portsmouth S, Bower M. Insights into the molecular biology and sero-epidemiology of Kaposi’s sarcoma. Curr. Opin. Infect. Dis.16, 25–31 (2003).
- Stebbing J, Bower M, Srivastava P. Kaposi’s sarcoma as a model for cancer immunotherapy. Trends Mol. Med.10, 187–193 (2004).
- Whelan M, Whelan J, Russell N, Dalgleish A. Cancer immunotherapy: an embarrassment of riches? Drug Discov. Today8, 253–258 (2003).
- Ward S, Casey D, Labarthe MC et al. Immunotherapeutic potential of whole tumour cells. Cancer Immunol. Immunother.51, 351–357 (2002).
- Finn OJ. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol.3, 630–641 (2003).
- Dalgleish AG, Whelan MA. Cancer vaccines as a therapeutic modality: the long trek. Cancer. Immunol. Immunother.55, 1025–1032 (2006).
- Slingluff CL Jr, Engelhard VH, Ferrone S. Peptide and dendritic cell vaccines. Clin. Cancer Res.12, S2342–S2345 (2006).
- Sondak VK, Sabel MS, Mule JJ. Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin. Cancer Res.12, S2337–S2341 (2006).
- Labarthe MC, Halanek N, Birchall L et al. The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model. Cancer. Immunol. Immunother.55, 277–288 (2006).
- Schnittger S, Schoch C. Quantitative PCR based minimal residual disease detection in core binding factor leukemias: prognostication and guiding of therapy. Leuk. Res.30, 657–658 (2006).
- Ireland R. Multimarker RT-PCR for detection of minimal residual disease in breast cancer patients. Nat. Clin. Pract. Oncol.3, 293 (2006).